Algeria vs Israel: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Algeria
0.1%
in 2024
Israel
0.1%
in 2024
Algeria rank
112th
Israel rank
112th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Algeria
- Israel
How they compare
Algeria currently reports 0.1% against 0.1% in Israel, a difference of 0.0%.
Across all 10 years both countries report, Israel has been ahead every year.
Algeria ranks 112th and Israel ranks 112th of 215 countries.
Israel has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Algeria | Israel | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.3% | 0.2% | Israel |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Algeria or Israel?
- Algeria, at 0.1% against 0.1% in Israel as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Algeria and Israel?
- 0.0%, with Algeria ahead.
- How many years of comparable data are there for Algeria and Israel?
- 10 years are reported by both, from 2015 to 2024.
- How do Algeria and Israel rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Algeria ranks 112th and Israel ranks 112th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.